Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well below the month’s 10-year historical average (22 IPOs, $5.1B). Six IPOs raised $100 million or more. With AI stocks under pressure in recent weeks,...read more
Three IPOs, one direct listing, and two SPACs priced during a challenging week for growth stocks. However, the week’s most notable news came from Anthropic (ANT), which filed its long awaited S-1 on Monday for an IPO that could be the largest ever. ...read more
Bambusa Therapeutics, a Phase 2 biotech developing bispecific antibodies for inflammatory diseases, raised $169 million by offering 10.6 million shares at $16, within the $15 to $17 range. At pricing, the company commands a fully diluted market value of $856...read more
Bambusa Therapeutics, a Phase 2 biotech developing bispecific antibodies for inflammatory diseases, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17....read more
Renaissance Capital’s October IPO Market Update
Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well below the month’s 10-year historical average (22 IPOs, $5.1B). Six IPOs raised $100 million or more. With AI stocks under pressure in recent weeks,...read more
US IPO Weekly Recap: Anthropic files for potentially record-breaking IPO
Three IPOs, one direct listing, and two SPACs priced during a challenging week for growth stocks. However, the week’s most notable news came from Anthropic (ANT), which filed its long awaited S-1 on Monday for an IPO that could be the largest ever. ...read more
Immunology and inflammation biotech Bambusa Therapeutics prices upsized IPO at $16 midpoint
Bambusa Therapeutics, a Phase 2 biotech developing bispecific antibodies for inflammatory diseases, raised $169 million by offering 10.6 million shares at $16, within the $15 to $17 range. At pricing, the company commands a fully diluted market value of $856...read more
Immunology and inflammation biotech Bambusa Therapeutics sets terms for $150 million IPO
Bambusa Therapeutics, a Phase 2 biotech developing bispecific antibodies for inflammatory diseases, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17....read more